Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brompheniramine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Brompheniramine maleate | EXPERIMENTAL | Brompheniramine maleate oral solution 1 mg/5 mL, single dose |
| Name | Type | Description |
|---|---|---|
| Brompheniramine maleate | DRUG | - |
Inclusion Criteria: 1. Males or females between 2 to less than 18 yrs of age with a minimum weight of 24 pounds and within the 5th and 95th percentiles in height and weight, and BMI based on age and gender 2. Symptomatic or asymptomatic children/adolescents as follows: * A prior diagnosis of al...
Brompheniramine is a small molecule being developed for the treatment of allergic reactions. It is currently in Phase 1 clinical development and is being studied in children and adolescents. The drug is being developed by Pfizer, Inc. (PFE).
Brompheniramine is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this drug for the treatment of allergic reactions in pediatric patients.
Brompheniramine is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 1 study has been completed, which evaluated the drug in children and adolescents with allergic reactions.
Brompheniramine has one completed clinical trial, NCT00894634, titled 'Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents.' This Phase 1 study enrolled 37 participants with allergic reactions, aged 2 years and older, and was not randomized, double-blind, or controlled.
Brompheniramine is an antihistamine that works by blocking the effects of histamine, a substance in the body that causes allergic symptoms. By inhibiting histamine receptors, it helps reduce symptoms associated with allergic reactions, such as sneezing, itching, and runny nose.